Navigation Links
Constipation Drug Linked to Heart Attack Pulled Out

Novartis AG, the Swiss pharmaceutical giant, has agreed to stop selling Zelnorm, a constipation drug, following complaints that it is linked// to higher chances of heart attack and stroke.

Officials of the Food and Drug Administration (FDA) of the US had advised the firm to pull the drug out of the market. (It is this Novartis that has challenged the rejection of its patent application for a cancer drug by Indian authorities. The suit has been filed in Madras High Court in southern India and the verdict is eagerly awaited as this is the first test case for India’s patent laws under the WTO regime.)

Earlier the FDA had approved Zelnorm, also called tegaserod maleate, for short-term treatment of women with irritable bowel syndrome with constipation.

It could also be used by those suffering from constipation but below 65 years of age.

It had been available in the market since 2002 and the FDA approval was granted in September 2004. Interestingly right at the time it was granting approval, the FDA had warned of diarrhea risks associated with the drug.

It said then that it had received several complaints of ischemic colitis, a condition resulting from reduced blood flow to the intestines, which in some cases can cause serious intestinal damage, and rarely death.

It had gone on to add, 'FDA is not thinking of taking Zelnorm off the market at this time. We are adding new information about potential risks of treatment with Zelnorm to the labeling so that doctors and patients can make informed individual treatment decisions.'

But now it says that it has concluded that the overall risk versus benefit profile for the drug is unfavorable for continued marketing.

Its request to Novartis was based on 'newly available information of an increased risk of serious cardiovascular adverse events, including myocardial infarction (heart attack), unstable angina (chest pain), and stroke, associated with us e of the drug.'

Doctors who prescribe Zelnorm should work with their patients and switch over to more appropriate treatment, the FDA has said.

Related medicine news :

1. Link between Constipation and Parkinsons Disease
2. Constipation can be a cause
3. Tegaserod offers relief for Chronic Constipation
4. Biofeedback Treats One Type Of Chronic Constipation
5. Low Cholesterol Linked to Severe Depression and Violent Behavior in Men
6. Cough Syrup Ingredient Linked to Stroke
7. Irregular Periods Linked to Diabetes
8. Hormones Linked To Migraines
9. Triglycerides Linked To Stroke Risk
10. Smoking Linked To Low Infant Birth Weight
11. Nausea Linked To Anxiety And Depression
Post Your Comments:

(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
Breaking Medicine Technology: